Introduction {#s1}
============

In the spring of 2020, the coronavirus disease 2019 (COVID-19) pandemic has spread to more than 200 countries around the world.[@R1] As of 27 March 2020, the total number of confirmed cases has exceeded 500 000.[@R3] This pandemic has become a serious threat to global health and continues to challenge healthcare systems worldwide. It was determined to be caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus 2.[@R4] Therefore, it is critical to understand and identify the key clinical and laboratory characteristics of patients with COVID-19 in order to help in early detection and isolation of infected individuals, as well as minimise the spread of the disease.[@R5]

Although a number of studies have attempted to explore this subject, most of them were single-centre studies that were conducted in a specific hospital or region. Due to differences in study design and small samples, the clinical symptoms, laboratory findings and other key outcomes of these studies are complicated and unclear.[@R6] For example, two recent systematic reviews[@R9] of studies of patients with COVID-19 indicated a high incidence of fever (\>88%) and cough (\>68%), but only one[@R10] reported symptoms of myalgia or fatigue (35.8%). Both reviews meta-analysed small samples pooled from 10 studies.

Therefore, the present meta-analysis was performed to provide the most extensive, up-to-date description so far of clinicopathological characteristics of patients with COVID-19 and to provide a reference for clinical decisions and future research.

Materials and methods {#s2}
=====================

Search strategy and study eligibility {#s2-1}
-------------------------------------

This meta-analysis was carried out based on the guidelines of the Preferred Reporting Items for Meta-Analyses of Observational Studies in Epidemiology Statement.[@R11] We systematically examined the studies on clinicopathological characteristics of patients with COVID-19 indexed in the PubMed, Embase, Chinese Biomedical Literature, Wanfang, China Science and Technology Journal Database and China National Knowledge Infrastructure databases between 1 January 2020 and 16 March 2020. All references cited in these studies were also analysed manually to ensure that eligible papers were not overlooked. If multiple studies analysed the same patient population, we included only the one with more detailed information or the one published more recently. No language restrictions were incorporated during the literature search, and only literature published online was included. The following keywords were used, both separately and in combination, as part of the search strategy in each database: 'Corona virus', 'Coronavirus', '2019-nCoV', 'COVID-19' or 'SARS-CoV-2' ([box 1](#B1){ref-type="boxed-text"}).

###### Search strings used for the PubMed database

\# 1 Corona virus \[Title/Abstract\]

\# 2 Coronavirus \[Title/Abstract\]

\# 3 2019-nCoV \[Title/Abstract\]

\# 4 COVID-19 \[Title/Abstract\]

\# 5 SARS-CoV-2 \[Title/Abstract\]

\# 6 \# 1 OR \# 2 OR \# 3 OR \# 4 OR \# 5

Studies were included in the meta-analysis if they had cohort, case--control or case series designs and provided sufficient details on clinical symptoms, laboratory outcomes and asymptomatic patients. Only studies of more than 40 patients were included.

Data extraction and quality assessment {#s2-2}
--------------------------------------

The literature selected was independently assessed by three reviewers based on the eligibility criteria, and relevant data were extracted. Disagreements were resolved by consensus. The titles and abstracts were first screened to identify the eligible articles, followed by a full-text review to obtain detailed information. When required, the authors were contacted directly to obtain further information and clarifications regarding their study. The following data were extracted from each included study: surname of first author; date of publication; study design; number, age and sex of patients; clinical and laboratory outcomes; and data relevant for assessing publication bias. The quality of observational case series was independently evaluated by the three reviewers based on the British National Institute for Clinical Excellence[@R12] guidelines. This evaluation was conducted based on a set of eight criteria, and studies with a score greater than 4 were considered to be of high quality (total score=8).

Statistical analyses {#s2-3}
--------------------

All statistical analyses were performed using STATA V.12. Original incidence rates *r* were transformed by the double arcsine method to ensure a normal distribution, and the resulting transformed rate *tr* was used in single-arm meta-analysis. The heterogeneity between studies was analysed using a χ^2^ test (p\<0.10) and quantified using the I^2^ statistic. When no statistical heterogeneity was observed, a fixed-effects model was used. Otherwise, potential sources of clinical heterogeneity were identified using subgroup and sensitivity analyses; these sources were eliminated, and the meta-analysis was repeated using a random-effects model. Pooled incidence rates *R* were back-calculated from transformed rates *tr* using the *R*=\[sin (*tr* / 2)\].[@R2] A two-tailed p\<0.05 was considered statistically significant. Publication bias was evaluated using a funnel plot along with Egger's regression test and Begg's test.

Results {#s3}
=======

Literature screening and assessment {#s3-1}
-----------------------------------

A total of 5576 records were identified from the various databases examined. After a detailed assessment based on the inclusion criteria, 55 unique studies[@R6] involving 8697 patients with COVID-19 were included in the meta-analysis ([figure 1](#F1){ref-type="fig"}).

![Flow chart depicting literature screening process.](fmch-2020-000406f01){#F1}

Characteristics of included studies {#s3-2}
-----------------------------------

All studies included in the meta-analysis were conducted in China and published between 6 February 2020 and 16 March 2020. These retrospective studies examined Chinese patients distributed across 31 provinces. A large proportion of these studies (n=40) were based on data collected from a single centre, with no clear explanation regarding eligibility criteria. Follow-up data were reported for most patients. All studies received quality scores of 5--8, indicating high quality ([table 1](#T1){ref-type="table"}).

###### 

Characteristics of included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                    Publication date   Sample size (n)   Study design                                Study population                                                                                                Age\*\         Follow-up                           Outcomes reported   Quality score
                                                                                                                                                                                                                            (years）                                                               
  ------------------------ ------------------ ----------------- ------------------------------------------- --------------------------------------------------------------------------------------------------------------- -------------- ----------------------------------- ------------------- ---------------
  Zhao*et al* [@R6]        March 3            101               Retrospective.                              Patients with COVID-19 in Radiology Quality Control Center, Hunan.                                              21--50         NA                                  ①                   7

  Xiong *et al* [@R7]      March 3            42                Retrospective.                              Patients with COVID-19 in Tongji Hospital, Huazhong University of Science and Technology.                       26--75         11 January--15 February             ①②                  7

  Zhou *et al* [@R8]       March 11           191               Retrospective, multicentre.                 Patients with COVID-19 in Wuhan Jinyintan Hospital and Wuhan Pulmonary Hospital.                                56.0           December 2019--31 January 2020      ①②                  7

  Li *et al* [@R13]        February23         54                Retrospective, single centre.               Patients with COVID-19 in Wuhan Fourth Hospital.                                                                51.5           January--February                   ①②                  7

  Xiao *et al* [@R14]      February 27        143               Retrospective, single centre.               Patients with COVID-19 in Chongqing Three Gorges Central Hospital.                                              45.1±1.0       23 January--8 February              ①②                  6

  Sun *et al* [@R15]       February 24        88                Retrospective, single centre.               Patients with COVID-19 in Tianjin Haihe Hospital.                                                               48.5±15.7      21 January--8 February 8            ①                   7

  Xu *et al* [@R16]        February 25        45                Retrospective, single centre.               Patients with COVID-19 in Hubei Provincial Hospital of Integrated Chinese and Western Medicine.                 54.58±17       22 January--5 February              ①                   7

  Lu *et al* [@R17]        February 10        50                Retrospective, single centre.               NA.                                                                                                             50.4±16.8      NA                                  ①②                  6

  Wang *et al* [@R18]      February 25        52                Retrospective, single centre.               Patients with COVID-19 in The First Affiliated Hospital of Zhejiang University.                                 44±14          9 January--3 February               ①                   6

  Liao *et al* [@R19]      February 26        42                Retrospective, single-centre cohort.        Patients with COVID-19 in Zhongnan Hospital of Wuhan University.                                                51.6           16 January--18 February             ②                   6

  Yu *et al* [@R20]        February 26        40                Retrospective, single centre.               Patients with COVID-19 in Wenzhou Sixth People′s Hospital.                                                      45.9           17 January--28 January              ①                   6

  Liu *et al* [@R21]       February 18        41                Retrospective, single centre.               Patients with COVID-19 in Xiaochang First People\'s Hospital.                                                   48.45          NA                                  ②                   6

  Cheng and Li[@R22]       February 19        54                Retrospective, single centre.               Patients with COVID-19 in The Affiliated Puren Hospital of Wuhan University of Science and Technology.          60.1±17        1 January--31 January               ①②                  7

  Yang *et al* [@R23]       March 3           57                Retrospective, single centre.               Patients with COVID-19 in Nanjing Public Health Medical Centre.                                                 37             NA                                  ①②                  7

  Xiang *et al* [@R24]      March 2           49                Retrospective, single centre.               Patients with COVID-19 in The First Affiliated of Nanjing University.                                           42.9           21 January--27 January              ①                   6

  Ma *et al* [@R25]        March 10           75                Retrospective, multicentre.                 Patients with COVID-19 from four hospitals in Fuyang City.                                                      43.9±15.1      20 January--18 February             ②                   7

  Xue *et al* [@R26]        March 10          66                Retrospective, single centre.               Patients with COVID-19 in Shanghai Public Health Clinical Center.                                               46.0±15.6      NA                                  ①                   6

  Gong *et al* [@R27]       March 9           225               Retrospective, single centre                Patients with COVID-19 in Chongqing Three Gorges Central Hospital.                                              0--82          20 January--16 February             ①                   7

  Ran *et al* [@R28]        March 6           209               Retrospective, multicentre.                 Patients with COVID-19 from four hospitals in Fuyang City.                                                      46.5±15.7      25 January--10 February             ①                   7

  Yuan *et al* [@R29]      March 6            223               Retrospective, single centre.               Patients with COVID-19 in Chongqing Public Medical Center.                                                      46.5±16.1      24 January--23 February             ①②                  6

  Shi *et al* [@R30]       March 5            67                Retrospective, single centre.               Patients with COVID-19 in Shanghai Public Health Clinical Center.                                               36±53.7        January--February                   ①                   7

  Xiong *et al* [@R31]     March 3            89                Retrospective, single centre.               Patients with COVID-19 in Renmin Hospital of Wuhan University.                                                  53±16.9        17 January--20 February             ①                   6

  Chen *et al* [@R32]      March 13           139               Retrospective, single centre.               Patients with COVID-19 in Chongqing Three Gorges Central Hospital.                                              15--79         January--February                   ①                   6

  Fang *et al* [@R33]      Machr 12           308               Retrospective, single centre.               Patients with COVID-19 in Hubei Huangshi Chinese Medicine Hospital.                                             30--86         25 January--20 February             ①                   7

  Zhou *et al* [@R34]      March 13           537               Retrospective, multicentre.                 All cases of COVID-19 in Shandong Province.                                                                     26--86         December 2019--15 February 2020     ①②                  7

  Li *et al* [@R35]        March 12           524               Retrospective, multicentre.                 COVID-19 patients from hospitals in Henan Province.                                                             45             2 January--20 February              ①                   8

  Song *et al* [@R36]      March 12           60                Retrospective, multicentre.                 Patients with COVID-19 in Gansu Provincial Designated Hospital.                                                 39.5±17.7      21 January--22 February             ①                   7

  Cheng *et al* [@R37]     Mar 12             463               Retrospective, single centre.               Patients with COVID-19 in Wuhan Jinyintan Hospital                                                              15--90         December 2019--6 February 2020      ①②                  6

  Chen *et al* [@R38]      March 10           76                Retrospective, single centre.               Patients with COVID-19 in Puren Hospital of Wuhan University of Science and Technology.                         59.5           January--February                   ①②                  6

  Cheng *et al* [@R39]     March 2            1079              Retrospective, multicentre.                 All cases of COVID-19 in Henan Province.                                                                        46             December 2019--29 February 2020     ①                   7

  Han *et al* [@R40]       March 16           150               Retrospective.                              Patients with COVID-19 from two hospitals in Wuhan.                                                             53±14          12 January--16 February             ①②                  6

  Xu *et al* [@R41]        March 16           62                Retrospective, single centre.               Critically ill patients with COVID-19 in Zhongnan Hospital of Wuhan University.                                 62.9           8 January--14 February              ①                   6

   Dong *et al* [@R42]     March 13           135               Retrospective, multicentre.                 All reported confirmed cases of COVID-19 in Tianjin.                                                            48.6±16.8      December 2019--24 February 2020     ①                   7

  Sun *et al* [@R43]       March 15           391               Retrospective.                              COVID-19 cases reported in Zhejiang province.                                                                   NA             NA                                  ①                   7

  Li *et al* [@R44]        February 29        83                Retrospective.                              Patients with COVID-19 in The Second Affiliated Hospital of Chongqing Medical University                        45.5±12.3      January--February                   ①②                  7

  Wu *et al* [@R45]        February 21        80                Retrospective, single centre.               Patients with COVID-19 from three tertiary hospitals in Jiangsu.                                                46.1           22 January--14 February             ①②                  7

  Xu *et al* [@R46]        February 28        90                Retrospective, single centre.               Patients with COVID-19 in Guangzhou Eighth People's Hospital.                                                   50             2 3January--4 February              ①②                  6

  Xu *et al* [@R47]        February 25        50                Retrospective, single centre.               Patients with COVID-19 in The Fifth Medical Centre of Chinese PLA General Hospital.                             NA             1 January--2 February               ①②                  6

  Yang *et al* [@R48]      February 26        149               Retrospective, multicentre.                 Patients with COVID-19 from three tertiary hospitals in Wenzhou.                                                45.1±13.4      17 January--10 February             ①②                  7

  Xu *et al* [@R49]        February 19        62                Retrospective, multicentre.                 Patients with COVID-19 from seven hospitals in Zhejiang Province.                                               41             10 January--26 January              ①②                  6

  Zhang *et al* [@R50]     February 23        140               Retrospective, single centre.               Patients with COVID-19 in No.7 Hospital in Wuhan.                                                               57.0           16 January--3 February              ①②                  6

  Wang *et al* [@R51]      February 8         138               Retrospective, single-centre case series.   Patients with COVID-19 in Zhongnan Hospital of Wuhan University.                                                56 (42--68）   1 January--28 January               ①②                  6

  Liu *et al* [@R52]       February 18        137               Retrospective, multicentre.                 Patients with COVID-19 from nine tertiary hospitals in Hubei Province.                                          55±16          30 December 2019--24 January 2020   ①②                  6

  Huang *et al* [@R53]     February 15        41                Retrospective, single centre.               Patients with COVID-19 in Hubei Province.                                                                       49 (41--58)    December 2019--2 January 2020       ①②                  6

  Chen *et al* [@R54]      February 15        99                Retrospective, single centre.               Patients with COVID-19 in Wuhan Jinyintan Hospital.                                                             55.5±13.1      1 January--20 January               ①②                  6

  Guan *et al* [@R55]      February 6         1099              Retrospective, multicentre.                 Patients with COVID-19 from 552 hospitals in 31 provinces.                                                      47.0           NA                                  ①②                  8

  Bernhem *et al* [@R56]   February 20        121               Retrospective case series.                  Patients with COVID-19 from four hospitals in four Chinese provinces.                                           45.3           18 January--2 February              ①                   8

  Wu *et al* [@R57]        February 21        80                Retrospective, multicentre.                 Patients with COVID-19 from three hospitals in Chongqing.                                                       44±11          January--February                   ①②                  7

  Shi *et al* [@R58]       February 21        81                Retrospective, multicentre cohort.          Patients with COVID-19 in Wuhan Jinyintan Hospital and Union Hospital of Tongji Medical College.                49.5--11.0     18 January--2 February              ①②                  7

  Yang *et al* [@R59]      February 24        52                Retrospective, single centre.               Critically ill patients with COVID-19 in Wuhan Jinyintan Hospital.                                              59.7--13.3     2 December 2019--23 January 2020    ①                   6

  Zhou *et al* [@R60]      March 5            62                Retrospective.                              Patients with COVID-19 in Huazhong University of Science and Technology.                                        52.8--12.2     16 January--30 January              ①②                  6

  Wang *et al* [@R61]      February 28        50                Retrospective, multicentre.                 Patients with COVID-19 from four hospitals in Jilin Province.                                                   44.5±16.1      28 January--21 February             ①                   8

  Fang *et al* [@R62]      February 25        79                Retrospective, single centre.               Patients with COVID-19 in Anhui Provincial Hospital.                                                            45.1±16.6      22 January--18 February             ①②                  5

  Yu *et al* [@R63]        February 17        40                Retrospective, single centre.               Patients with COVID-19 in the Chinese People\'s Liberation Army General Hospital.                               39.9±18.2      21 January--February                ①②                  6

  Zhang *et al* [@R64]     February 19        42                Retrospective, single centre.               Patients with COVID-19 in Nanjing Hospital, affiliated to Nanjing University of Traditional Chinese Medicine.   43±16.8        19 January--February                ①②                  5
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

① Clinical symptoms; ② laboratory findings.

\*Reported variously as range or mean±SD or median, and IQR values.

NA, not reported.

Meta-analysis results {#s3-3}
---------------------

### Gender distribution {#s3-3-1}

Relevant data regarding the clinicopathological characteristics of 8697 patients with COVID-19 was collected.[@R6] Significant heterogeneity was observed across all included studies (I^2^=93.7%), therefore, a random-effects model was used in the meta-analysis. We found that 53.3% (95%CI 50.3 to 56.4) of the patients were male.

### Clinical symptoms {#s3-3-2}

Two major symptoms, including fever (78.4%) and cough (58.3%), were highly prevalent among patients. Fatigue (34%), myalgia (21.9%), expectoration (23.7%), anorexia (22.9%), chest tightness (22.9%) and dyspnoea (20.6%) also occurred frequently. Less frequent symptoms were nausea and vomiting (6.6%), diarrhoea (8.2%), headache (11.3%), pharyngalgia (11.6%), shivering (15.2%) and rhinorrhea (7.3%). Only 5.4% of patients with COVID-19 were found to be asymptomatic ([table 2](#T2){ref-type="table"}).

###### 

Clinical symptoms observed in patients with COVID-19

  Symptom               No. of studies   No. of patients   Heterogeneity   Model   Meta-analysis                            
  --------------------- ---------------- ----------------- --------------- ------- --------------- ------------------------ ---------
  Fever                 51               8473              \<0.001         95.9    Random          0.784 (0.736 to 0.828)   \<0.001
  Cough                 52               8539              \<0.001         97.2    Random          0.583 (0.515 to 0.649)   \<0.001
  Fatigue               45               7848              \<0.001         96.9    Random          0.340 (0.277 to 0.405)   \<0.001
  Myalgia               37               5625              \<0.001         93.0    Random          0.219 (0.177 to 0.264)   \<0.001
  Headache              34               6414              \<0.001         88.5    Random          0.113 (0.089 to 0.140)   \<0.001
  Diarrhoea             43               7904              \<0.001         87.5    Random          0.082 (0.064 to 0.102)   \<0.001
  Expectoration         33               6408              \<0.001         95.8    Random          0.237 (0.185 to 0.294)   \<0.001
  Dyspnoea              25               3670              \<0.001         87.5    Random          0.206 (0.133 to 0.290)   \<0.001
  Chest tightness       30               5773              \<0.001         97.2    Random          0.229 (0.163 to 0.304)   \<0.001
  Nausea and vomiting   24               4941              \<0.001         82.2    Random          0.066 (0.048 to 0.086)   \<0.001
  Pharyngalgia          31               5947              \<0.001         88.7    Random          0.116 (0.090 to 0.145)   \<0.001
  Rhinorrhoea           13               3111              \<0.001         91.2    Random          0.073 (0.042 to 0.113)   \<0.001
  Anorexia              19               3274              \<0.001         96.9    Random          0.229 (0.143 to 0.326)   \<0.001
  Shivering             16               4394              \<0.001         96.8    Random          0.152 (0.090 to 0.228)   \<0.001
  Asymptomatic          10               878               0.002           66.3    Random          0.054 (0.031 to 0.084)   \<0.001

### Pathological characteristics {#s3-3-3}

A large proportion of patients had normal leucocyte counts (64.7%) and high levels of C reactive protein (65.9%) ([figures 2 and 3](#F2 F3){ref-type="fig"}). Lymphopaenia was observed in many patients (47.6%), along with elevated levels of myocardial enzymes (49.4%) and abnormal liver function (26.4%). Also observed were leucopenia (23.5%), leucocytosis (9.9%), abnormal renal function (10.9%), elevated levels of D-dimer (20.4%), elevated erythrocyte sedimentation rate (20.4%) and elevated procalcitonin (16.7%) ([table 3](#T3){ref-type="table"}).

###### 

Pathological characteristics of patients with COVID-19

  Characteristic                        No. of studies   No. of patients   Heterogeneity   Model   Meta-analysis                            
  ------------------------------------- ---------------- ----------------- --------------- ------- --------------- ------------------------ ---------
  Leucocytosis                          21               3936              \<0.001         90.6    Random          0.099 (0.069 to 0.134)   \<0.001
  Normal leucocyte count                23               3267              \<0.001         89.5    Random          0.647 (0.591 to 0.700)   \<0.001
  Leucopenia                            27               4233              \<0.001         89.6    Random          0.235 (0.194 to 0.279)   \<0.001
  Lymphopaenia                          32               4660              \<0.001         94.4    Random          0.476 (0.413 to 0.540)   \<0.001
  High C reactive protein               23               2912              \<0.001         93.2    Random          0.659 (0.586 to 0.728)   \<0.001
  High procalcitonin                    13               2190              \<0.001         96.6    Random          0.167 (0.083 to 0.274)   \<0.001
  High D-dimer                          9                2354              \<0.001         90.4    Random          0.204 (0.147 to 0.267)   \<0.001
  High erythrocyte sedimentation rate   7                455               \<0.001         90.4    Random          0.204 (0.147 to 0.267)   \<0.001
  Abnormal liver function               11               2524              \<0.001         90.1    Random          0.264 (0.204 to 0.329)   \<0.001
  Abnormal renal function               8                2183              \<0.001         96.1    Random          0.109 (0.045 to 0.196)   \<0.001
  High myocardial enzymes               11               2541              \<0.001         96.1    Random          0.494 (0.264 to 0.725)   \<0.001

![Transformed incidence rate of normal leucocyte count in patients with COVID-19.](fmch-2020-000406f02){#F2}

![Transformed incidence rate of high C reactive protein levels in patients with COVID-19.](fmch-2020-000406f03){#F3}

### Subgroup analysis {#s3-3-4}

Patients were stratified into two groups based on the date of initial diagnosis: group 1 included all patients and group 2 included those diagnosed between December 2019 and 31 January 2020 ([table 4](#T4){ref-type="table"}). We found that all patients diagnosed before 31 January had higher incidence rates of fever and cough. No significant difference was observed in the heterogeneity between the subgroups and the overall heterogeneity, indicating that the date of initial diagnosis was not the main source of heterogeneity.

###### 

Analysis of clinical symptoms observed in patients with COVID-19, stratified by date of initial diagnosis\*

  Clinical symptom   No. of studies   No. of patients   Heterogeneity   Model   Meta-analysis                            
  ------------------ ---------------- ----------------- --------------- ------- --------------- ------------------------ ---------
  Fever                                                                                                                  
   Group 1           51               8473              \<0.001         95.9    Random          0.784 (0.736 to 0.828)   \<0.001
   Group 2           14               2162              \<0.001         97.9    Random          0.813 (0.667 to 0.924)   \<0.001
  Fatigue                                                                                                                
   Group 1           45               7848              \<0.001         96.9    Random          0.340 (0.277 to 0.405)   \<0.001
   Group 2           11               1971              \<0.001         93.9    Random          0.366 (0.268 to 0.470)   \<0.001
  Cough                                                                                                                  \<0.001
   Group 1           52               8539              \<0.001         97.2    Random          0.583 (0.515 to 0.649)   \<0.001
   Group 2           14               2162              \<0.001         86.6    Random          0.640 (0.574 to 0.703)   \<0.001
  Myalgia                                                                                                                \<0.001
   Group 1           37               5625              \<0.001         93.0    Random          0.219 (0.177 to 0.264)   \<0.001
   Group 2           10               1938              \<0.001         91.7    Random          0.271 (0.193 to 0.358)   \<0.001

\*Group 1: all patients; group 2: diagnosed before 31 January 2020.

### Sensitivity analysis {#s3-3-5}

A sensitivity analysis was carried out by excluding one study at a time and reanalysing the entire dataset. We found that the pooled incidence rates did not change substantially, indicating the reliability and stability of our meta-analysis (eg, [figure 4](#F4){ref-type="fig"}).

![Sensitivity analysis of the incidence rate of expectoration in patients with COVID-19.](fmch-2020-000406f04){#F4}

Evaluation of publication bias {#s3-4}
------------------------------

The p values derived using the Egger's and the Begg's test for all the clinicopathological characteristics showed no obvious publication bias ([table 5](#T5){ref-type="table"}). A funnel plot based on the incidence rate of fever showed p values of 0.091 in Egger's test and 0.703 in Begg's test ([figure 5](#F5){ref-type="fig"}). These results confirm that there is no publication bias.

###### 

Evaluation of publication bias using the Egger's and the Begg's test

  Characteristic        P (Egger's)   P (Begg's)   Characteristic                        P (Egger's)   P (Begg's)
  --------------------- ------------- ------------ ------------------------------------- ------------- ------------
  Fever                 0.091         0.703        Shivering                             0.642         0.137
  Cough                 0.259         0.776        Asymptomatic                          0.840         0.589
  Fatigue               0.094         0.018        Leucocytosis                          0.087         0.238
  Myalgia               \<0.001       \<0.001      Normal leucocyte count                0.760         0.195
  Headache              0.034         0.015        Leucopenia                            0.790         0.587
  Diarrhoea             0.001         0.004        Lymphopenia                           0.062         0.910
  Expectoration         0.208         0.018        High C reactive protein               0.001         0.138
  Dyspnoea              0.386         0.088        High procalcitonin                    0.022         0.222
  Chest tightness       0.234         0.164        High D-dimer                          0.363         0.466
  Nausea and vomiting   0.102         0.092        High erythrocyte sedimentation rate   0.028         0.048
  Pharyngalgia          0.089         0.086        Abnormal liver function               0.050         0.640
  Rhinorrhea            0.748         0.059        Abnormal renal function               0.015         0.686
  Anorexia              0.002         0.006        High myocardial enzymes               0.791         0.350

![Evaluation of publication bias using a funnel plot based on the incidence rate of fever.](fmch-2020-000406f05){#F5}

Discussion {#s4}
==========

In this meta-analysis, we examined 55 independent studies[@R6] reporting clinicopathological data on 8697 patients with COVID-19 distributed across 31 provinces in China. The studies included in this analysis comprise the latest research available on COVID-19 through 16 March 2020. Our results indicate that there is a slightly higher proportion of male patients (53.3%) and that the main symptoms of this disease are fever (78.4%), cough (58.3%) and fatigue (34%). Compared with previous results,[@R9] our findings reveal lower incidence rates of the two major symptoms of this disease, which we found to depend to some extent on whether diagnosis was made before or after 31 January 2020, reflecting with the progress of the epidemic, the number of atypical manifestations has growed gradually. For example, some patients developed gastrointestinal symptoms, such as diarrhoea, nausea and vomiting. These results highlight the importance of also taking into account non-respiratory symptoms of the disease.

Most patients with COVID-19 showed normal leucocyte counts and lymphopqenia. Few patients had leucocytosis and elevated procalcitonin levels, confirming that this disease is transmitted by a virus. Therefore, it is essential for clinicians to use such pathological findings to rule out the presence of bacterial infections. In this study, 49.4% of the patients presented with myocardial enzyme spectrum abnormalities, which manifested as an increase in lactate dehydrogenase levels. Studies have shown that elevated levels of lactate dehydrogenase can be a risk factor for rapid progression from mild to critical COVID-19.[@R65] Therefore, monitoring the function of important organs during treatment is critical, and treatment should be adjusted as needed to preserve and maintain organ function.

Infected people who are asymptomatic can act as a source of infection,[@R66] especially since the estimated median incubation period is 5--6 days (range 0--14 days). An analysis by the Chinese Center for Disease Control and Prevention conducted through 17 February 2020 suggested that the proportion of asymptomatic patients was only around 1%,[@R67] but our results suggest that the proportion is closer to 5%. This increase may reflect the growing experience of hospitals with this novel disease and increasing screening of suspected COVID-19 cases for viral infection, allowing the correct diagnosis of greater proportions of patients showing no or less typical manifestations. Therefore, to control the spread of this disease, general practitioners should carefully monitor individuals with histories of contact in areas where outbreaks have occurred or who had contact with suspected or confirmed cases of COVID-19 within 14 days before onset of symptoms.[@R68] Epidemiological history of patients should be investigated in detail, and asymptomatic infected people in the community should be identified as quickly as possible to control spread of the disease.

A recent study suggests that, considering different scenarios, highly eﬀective contact tracing and case isolation are sufficient to control a new outbreak of COVID-19 within 3 months.[@R69] Therefore, isolation, quarantine, social distancing, and community containment measures should be rapidly implemented in high-risk countries or regions.[@R70] In China, community engagement has been the first line of defence in the battle against the COVID-19 pandemic. General practitioners act as both gatekeepers and health promoters by educating the public and guiding the community in the fight against this disease.[@R71] Monitoring people at designated checkpoints, intercepting transmission routes in a timely manner and preventing local outbreaks are critical to prevent repeat epidemics.[@R72]

Although this study rigorously analysed clinical and laboratory data collected from a large sample of patients with COVID-19, we were unable to eliminate the significant heterogeneity observed between studies. For example, the course and the severity of the disease varied across studies. Given that most of the studies included in our meta-analysis were single-centre, retrospective studies, it was difficult for us to control for the effects of several confounding factors, including bias in patient admission and selection, as well as differences in disease severity and course. Further research is required to verify and extend our results for China. Continued surveillance across multiple countries, along with transparent and accurate reporting of patient characteristics and testing policies, will help us gain a better understanding of this global pandemic.[@R73]

Conclusion {#s5}
==========

In summary, Current evidence showed that the most commonly experienced symptoms of patients with COVID-19 were fever and cough. Myalgia, anorexia, chest tightness and dyspnoea were found in some patients. A relatively small percentage of patients were asymptomatic and could act as carriers of the disease. Most patients showed normal leucocyte counts, elevated levels of C reactive protein and lymphopenia, confirming the viral origin of the disease. Due to limited quality and quantity of the included studies, more high-quality prospective studies are required to verify above conclusions.
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